-
Genes & Genomics Sep 2019The peripheral nervous system (PNS) is composed with all nerves extended from the brain and spinal cord, which are the central nervous system to other organs of the... (Review)
Review
The peripheral nervous system (PNS) is composed with all nerves extended from the brain and spinal cord, which are the central nervous system to other organs of the body. Dysfunctional peripheral motion resulting from the regressive neuronal axons in the defected PNS leads to several peripheral neuropathies including both inherited and non-inherited disorders. Because of poor understanding of cellular and molecular mechanisms involved in the peripheral neuropathy, there is currently non-targeted treatment of the disorder. Basic researches have paid attention to dissect roles of causative genes, identified from the inherited peripheral neuropathies, in PNS development. However, recent studies focusing on investigation of therapeutic targets have suggested that successful regeneration of the impaired peripheral nerves may be most effective treatment. The regeneration studies have been limited in the rodents system due to some of practical and physiological disadvantages until zebrafish model has emerged as an ideal system. Hence, this review aims to provide a comprehensive overview of the advantages of zebrafish as a model for the peripheral neuropathy researches and to suggest the disease genes-involved potential mechanisms targeting the PNS regeneration that may be demonstrated in zebrafish.
Topics: Animals; Disease Models, Animal; Peripheral Nervous System Diseases; Zebrafish; Zebrafish Proteins
PubMed: 31183681
DOI: 10.1007/s13258-019-00838-2 -
Journal of Pain & Palliative Care... Sep 2020Chemotherapy-induced peripheral neuropathy (CIPN) is a chronic symptom associated with chemotherapy treatment. Symptoms and severity vary based on chemotherapeutic agent... (Review)
Review
Chemotherapy-induced peripheral neuropathy (CIPN) is a chronic symptom associated with chemotherapy treatment. Symptoms and severity vary based on chemotherapeutic agent used and dose. At present, effective options for the prevention and treatment of CIPN are inadequate and clinical guidance is limited. Unknown mechanism of action, lack of efficacy in many traditional neuropathic pain medications, and inconsistent evidence in regard to drug therapy have further complicated evaluation of therapeutic options. Twenty-five studies were identified and evaluated for CIPN prevention and treatment potential. Findings for CIPN pharmacological prevention were inconclusive as literature was largely conflicting. Exercise may be an effective non-pharmacological CIPN prevention method with limited adverse effects, however additional supporting data is still required. For treatment of CIPN, pharmacological agents duloxetine and topical combination product containing baclofen, amitriptyline, and ketamine have data supporting use. Early stage trials have shown initial promise for non-pharmacological therapies Scrambler Therapy and Photobiomodulation. Significant research is required as CIPN symptoms can lead to decreased quality of life, chemotherapy dose reduction, and discontinuation of drug therapy.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Neuralgia; Pain Management; Peripheral Nervous System Diseases; Quality of Life
PubMed: 32118502
DOI: 10.1080/15360288.2020.1734144 -
Nutrients Jan 2022Chemotherapy-induced peripheral neuropathy (CIPN) is one of the main and most prevalent side effects of chemotherapy, significantly affecting the quality of life of... (Review)
Review
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the main and most prevalent side effects of chemotherapy, significantly affecting the quality of life of patients and the course of chemotherapeutic treatment. Nevertheless, despite its prevalence, the management of the CIPN is considered particularly challenging, with this condition often being perceived as very difficult or even impossible to prevent with currently available agents. Therefore, it is imperative to find better options for patients diagnosed with this condition. While the search for the new agents must continue, another opportunity should be taken into consideration-repurposing of the already known medications. As proposed, acetyl-L-carnitine, vitamins (group B and E), extracts of medical plants, including goshajinkigan, curcumin and others, unsaturated fatty acids, as well as the diet composed of so-called "sirtuin-activating foods", could change the typical way of treatment of CIPN, improve the quality of life of patients and maintain the continuity of chemotherapy. This review summarizes currently available data regarding mentioned above agents and evaluates the rationale behind future research focused on their efficacy in CIPN.
Topics: Antineoplastic Agents; Dietary Supplements; Humans; Peripheral Nervous System Diseases; Quality of Life; Vitamins
PubMed: 35276984
DOI: 10.3390/nu14030625 -
Current Oncology Reports Jan 2004Peripheral neuropathy has a major impact on quality of life and may limit the amount of treatment patients can receive. Neurotoxic agents are used increasingly in... (Review)
Review
Peripheral neuropathy has a major impact on quality of life and may limit the amount of treatment patients can receive. Neurotoxic agents are used increasingly in oncologic practice, yet clinicians are often unaware of the protean manifestations of neuropathy and find its management troubling. Recent knowledge about the mechanisms of neuropathic disease and new treatments may help to minimize the impact of neuropathy on this vulnerable patient population.
Topics: Antineoplastic Agents; Humans; Neoplasms; Nerve Growth Factors; Pain; Peripheral Nervous System Diseases; Quality of Life; Reflex, Stretch
PubMed: 14664756
DOI: 10.1007/s11912-996-0005-9 -
Current Oncology Reports Apr 2020Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of numerous chemotherapy drugs. CIPN negatively impacts function and quality of life during and... (Review)
Review
PURPOSE OF REVIEW
Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of numerous chemotherapy drugs. CIPN negatively impacts function and quality of life during and after treatment. We will provide a review of the data describing the physical consequences of CIPN and discuss the possible long term impact on emotional well-being and quality of life.
RECENT FINDINGS
CIPN negatively affects physical function and many aspects of quality of life. Exercise interventions are likely to reduce the risk of falls associated with CIPN. There remains a need for evidence-based interventions focused on improving symptoms, function, and quality of life in persons with CIPN.
Topics: Accidental Falls; Antineoplastic Agents; Humans; Peripheral Nervous System Diseases; Physical Functional Performance; Postural Balance; Quality of Life; Sleep
PubMed: 32323068
DOI: 10.1007/s11912-020-00903-0 -
Critical Reviews in Neurobiology 1988Peripheral neuropathy has been associated with monoclonal gammopathy in patients with Waldenstrom's macroglobulinemia, myeloma, B-cell lymphoma, and nonmalignant plasma... (Review)
Review
Peripheral neuropathy has been associated with monoclonal gammopathy in patients with Waldenstrom's macroglobulinemia, myeloma, B-cell lymphoma, and nonmalignant plasma cell dyscrasia. The neuropathy in these patients is heterogeneous and may be demyelinating or axonal, and sensory-motor or pure motor. The cause of neuropathy in many patients is unknown, but there is increasing evidence that in some cases it may be caused by autoantibody activity of M-proteins that bind to peripheral nerve antigens. Significant advances have been made in characterizing the autoantibody activity of M-proteins and correlating antigenic specificity with the type of neuropathy present, in elucidating the effector mechanisms responsible for causing nerve injury, and in understanding the causes for the aberrant immune response. This article reviews the recent advances made in this field and discusses their implications for the clinical evaluation and management of patients with peripheral neuropathy and monoclonal gammopathy.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Myelin Proteins; Myelin-Associated Glycoprotein; Paraproteinemias; Peripheral Nervous System Diseases
PubMed: 2458847
DOI: No ID Found -
Fortschritte Der Neurologie-Psychiatrie Aug 2015Chemotherapy-induced peripheral neuropathy (CIPN) is a common and relevant side effect of antineoplastic agents such as cisplatin, paclitaxel, vincristine and... (Review)
Review
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and relevant side effect of antineoplastic agents such as cisplatin, paclitaxel, vincristine and bortezomib. Over the last years, significant progress has been achieved in elucidating the underlying pathomechanisms of CIPN using both in vivo and in vitro models. These studies suggest that mitochondrial toxicity, disturbed axonal transport, toxic effects on Schwann cells and activation of the immune system contribute to the pathogenesis of CIPN. This review provides an overview of the current pathogenetic concepts of CIPN. In addition, experimental approaches that aim at preventing or ameliorating neurotoxic effects of antineoplastic agents are discussed.
Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Peripheral Nervous System Diseases
PubMed: 26327474
DOI: 10.1055/s-0035-1553475 -
Anticancer Research Oct 2022Chemotherapy-induced peripheral neuropathy (CIPN) develops as a challenging nerve-damaging adverse effect of anticancer drugs used in chemotherapy. The disorder may... (Review)
Review
Chemotherapy-induced peripheral neuropathy (CIPN) develops as a challenging nerve-damaging adverse effect of anticancer drugs used in chemotherapy. The disorder may require a chemotherapy dose reduction and a cessation of administration of chemotherapeutic drugs. Its principal sensory symptoms include, tingling, and numbness in the hands and feet. Severe pain can be encompassed among clinical manifestations. CIPN affects dramatically the patient's quality of life (QoL). Pain and sensory symptoms may occur for months, or even years after the termination of chemotherapeutic drugs. Although many pharmacological and non-pharmacological therapeutic approaches have been tested to overcome these symptoms, there is currently no standardized treatment for CIPN. According to current guidelines, Duloxetine is the only recommended agent for painful neuropathic symptoms. Therefore, finding effective therapies for CIPN is mandatory. The aim of this review was to dissect CIPN, the target and immunotherapy-based approaches to this disorder, as well as to offer new insights for new therapeutic perspectives.
Topics: Antineoplastic Agents; Duloxetine Hydrochloride; Humans; Pain; Peripheral Nervous System Diseases; Quality of Life
PubMed: 36191965
DOI: 10.21873/anticanres.15971 -
Seminars in Musculoskeletal Radiology Apr 2015Peripheral nerves traverse through different soft tissue compartments in the upper and lower extremities via specific anatomical tunnels, where they are susceptible to... (Review)
Review
Peripheral nerves traverse through different soft tissue compartments in the upper and lower extremities via specific anatomical tunnels, where they are susceptible to entrapment. Common sites in the upper extremity include carpal tunnel, cubital tunnel and radial tunnel. Common sites in the lower extremity include piriformis, fibular neck, and tarsal tunnel. Compressive peripheral neuropathy can develop in these sites, and are amenable for surgical decompression.
Topics: Decompression, Surgical; Diagnostic Imaging; Humans; Nerve Compression Syndromes; Peripheral Nerves; Peripheral Nervous System Diseases
PubMed: 25764236
DOI: 10.1055/s-0035-1547518 -
Journal of Neuroimmunology Jun 2021A large proportion of older individuals with diabetes go on to develop diabetic peripheral neuropathy (DPN). DPN is associated with an increase in inflammatory cells... (Review)
Review
A large proportion of older individuals with diabetes go on to develop diabetic peripheral neuropathy (DPN). DPN is associated with an increase in inflammatory cells within the peripheral nerve, activation of nuclear factor kappa-light-chain-enhancer of activated B cells and receptors for advanced glycation end products/advanced glycation end products pathways, aberrant cytokine expression, oxidative stress, ischemia, as well as pro-inflammatory changes in the bone marrow; all processes that may be exacerbated with age. We review the immunological features of DPN and discuss whether age-related changes in relevant immunological areas may contribute to age being a risk factor for DPN.
Topics: Aging; Diabetes Mellitus; Diabetic Neuropathies; Humans; Immunity; Immunotherapy; Peripheral Nervous System Diseases
PubMed: 33894676
DOI: 10.1016/j.jneuroim.2021.577574